Navigation Links
Champions Biotechnology Awarded $1.46 million in Grants

BALTIMORE, Nov. 3, 2010 /PRNewswire/ -- Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, today received $1.46 million in grants as part of the Qualifying Therapeutic Discovery Project ("QTDP"). The QTDP was enacted as part of the Patient Protection and Affordable Care Act of 2010.

About Champions Biotechnology, Inc. Champions Biotechnology, Inc. is engaged in the development of advanced preclinical platforms and predictive tumor specific data to enhance and accelerate the value of oncology drugs.  The Company's Preclinical Platform is a novel approach based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting xenografts (Biomerk Tumorgrafts™) in a manner that preserves the biological characteristics of the original human tumor.  The Company believes that these Tumorgrafts closely reflect human cancer biology and their response to drugs is more predictive of clinical outcomes in cancer patients.

Champions Biotechnology leverages its preclinical platform to evaluate drug candidates and to develop a portfolio of novel therapeutic candidates.  The Company also offers its predictive preclinical platform and tumor specific data to physicians for personalized patient care and to Companies for evaluation of oncology drugs and drug candidates in models that integrate prognostic testing with biomarker discovery.

Champions Biotechnology is dedicated to enhancing preclinical development tools, accelerating development and valuation of oncology drugs, and advancing personalized treatment with a goal to improve the lives of cancer patients globally.

This press release contains "forward-looking statements" (within the meaning of the Private Securities Litigation Act of 1995) that inherently involve risk and uncertainties.  Champions Biotechnology generally uses words such as "believe," "may," "could," "will," "intend," "expect," "anticipate," "plan," and similar expressions to identify forward-looking statements.  One should not place undue reliance on these forward-looking statements.  The Company's actual results could differ materially from those anticipated in the forward-looking statements for many unforeseen factors.  See Champions Biotechnology's Form 10-K for the fiscal year ended April 30, 2010 for a discussion of such risks, uncertainties and other factors.  Although the Company believes the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made, and Champions Biotechnology's future results, levels of activity, performance or achievements may not meet these expectations.  The Company does not intend to update any of the forward-looking statements after the date of this press release to conform these statements to actual results or to changes in Champions Biotechnology's expectations, except as required by law.

CHAMPIONS BIOTECHNOLOGY, INC. WEB SITE: www.championsbiotechnology.comContact: James CarbonaraThe Investor Relations Group, Inc. 212-825-3210For Champions Biotechnology, Inc.

SOURCE Champions Biotechnology, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
2. Champions Biotechnology Begins Preclinical Development of Its Lead Oncology Drug Candidate
3. U.S. Patent Issued for Champions Biotechnologys Lead Oncology Drug
4. Champions Biotechnology, Inc. Signs Exclusive Licensing Agreement with Ramot for TAR-1, a Novel Therapeutic for the Treatment of Cancer
5. Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results
6. Higher Education Leaders Receive TCWF Champions of Health Professions Diversity Award
7. Champions Biotechnology Announces Agreement With Cephalon for the Evaluation of a Novel Oncology Compound Using Predictive Biomerk Tumorgraft™ Platform
8. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
9. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
10. Lixte Biotechnology Holdings, Inc. Announces Completion of Private Placement
11. Lixte Biotechnology Holdings Announces That Anti-Cancer Activity Against Glioblastoma in an Animal Model Was Reported at the Annual Meeting of the American Association of Cancer Research
Post Your Comments:
(Date:10/13/2015)... VEGAS , Oct. 13, 2015 VIVA ... of vascular medicine and intervention through education and research, ... annual conference,  VIVA 2015 . Sixteen trial results, featuring ... released for the first time on Monday and Tuesday, ... --> --> Since ...
(Date:10/13/2015)... , Oct. 13, 2015  Kay Elledge, ... and Fellow American College of Obstetrics and Gynecology ... evolve by establishing the Genuine Self Medical Laser ... and men.  In recognition of Breast Cancer ... special promotion for MonaLisa Touch treatments ...
(Date:10/13/2015)... PITTSBURGH , Oct. 13, 2015  Mylan N.V. (Nasdaq: ... at 5:00 p.m. ET host a conference call and webcast ... Company plc (NYSE: PRGO ; TASE) shareholders through Mylan,s ... by Mylan,s Executive Chairman Robert J. Coury , CEO ... --> --> Mylan ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... October 13, 2015 , ... ... of Excellence in the Life Sciences Initiative aimed at enhancing Purdue’s life sciences ... $2 billion “Ever True” capital campaign. , The investment will result in cohesive ...
(Date:10/13/2015)... West Palm Beach, FL (PRWEB) , ... October 13, 2015 , ... ... acquisition of Global Laser Vision of San Diego, California. With brands including The LASIK ... 3.3 million successful procedures, making it the nationwide leader in laser vision correction. , ...
(Date:10/13/2015)... N.J. (PRWEB) , ... October 13, 2015 , ... ... media enterprise focused on cancer patients, today announced a new partnership with the ... patients battling this rare type of non-Hodgkin’s lymphoma, their families and physicians. ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... ... beverage companies in the United States, today announced the release of its limited ... and new Cranberry Cocktail Agua Fresca. All feature the unique flavor combinations and ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... technology platform, ENGAGE, at HIMSS’s Patient Engagement Summit . HealthAware is a ... delivers innovative health programs and interventions via mobile devices that provide a framework ...
Breaking Medicine News(10 mins):